Cost‐effectiveness of antipsychotics for outpatients with chronic schizophrenia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International journal of clinical practice

• Publication date

  2007-12-01

• Fields of study

  Medicine, Economics, Psychology

• Identifiers
  DOI 10.1111/j.1742-1241.2007.01431.xPMID 17997804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

  2012cited by this paper
• Comments on ‘Cost‐effectiveness of antipsychotics for outpatients with chronic schizophrenia’

  2008cited by this paper
• Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

  2006cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

  2005cited by this paper
• Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

  2005cited by this paper
• Impact of atypical antipsychotics on outcomes of care in schizophrenia.

  2005cited by this paper
• Ambulatory Use of Olanzapine and Risperidone: A Population-Based Study on Persistence and the Use of Concomitant Therapy in the Treatment of Schizophrenia

  2005cited by this paper
• Pharmacoeconomic evaluation of schizophrenia in Taiwan: Model comparison of long‐acting risperidone versus olanzapine versus depot haloperidol based on estimated costs

  2005cited by this paper
• Amisulpride

  2004cited by this paper
• The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

  2004cited by this paper
• Relapse in schizophrenia: costs, clinical outcomes and quality of life

  2004cited by this paper
• Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.

  2004cited by this paper
• Dose Response and Dose Equivalence of Antipsychotics

  2004cited by this paper
• Adherence to conventional and atypical antipsychotics after hospital discharge.

  2004cited by this paper
• A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

  2004cited by this paper
• Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

  2004cited by this paper
• A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

  2004cited by this paper
• Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.

  2003cited by this paper
• Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.

  2003cited by this paper
• Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications *

  2003cited by this paper
• Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

  2003cited by this paper
• Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

  2003cited by this paper
• A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

  2003cited by this paper
• A meta-analysis of the efficacy of second-generation antipsychotics.

  2003cited by this paper
• Relapse and rehospitalization: comparing oral and depot antipsychotics.

  2003cited by this paper
• Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6-month Double-blind Study

  2002cited by this paper
• A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

  2002cited by this paper
• Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial

  2002cited by this paper
• Relapse and Rehospitalisation Rates in Patients with Schizophrenia

  2002cited by this paper
• Prevalence and Incidence Studies of Schizophrenic Disorders: A Systematic Review of the Literature

  2002cited by this paper
• A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.

  2002cited by this paper
• Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.

  2002cited by this paper
• Antipsychotic medication adherence: is there a difference between typical and atypical agents?

  2002cited by this paper
• Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.

  2001cited by this paper
• Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

  2001cited by this paper
• Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes.

  2001cited by this paper
• Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.

  2001cited by this paper
• Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample

  2000cited by this paper
• Cost Analysis of the Treatment of Schizophrenia in the UK

  2000cited by this paper
• Predicting medication noncompliance after hospital discharge among patients with schizophrenia.

  2000cited by this paper
• Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.

  1999cited by this paper
• Risperidone versus haloperidol: II. Cost-effectiveness.

  1998cited by this paper
• Do drugs have a place in the treatment of eating disorders in adolescence?

  1998cited by this paper
• Influence of antipsychotic profile on cost of treatment of schizophrenia: A decision analysis approach.

  1998cited by this paper
• Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

  1998cited by this paper
• Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model

  1998cited by this paper
• A cost-effectiveness clinical decision analysis model for schizophrenia.

  1998cited by this paper
• Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

  1997cited by this paper
• Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

  1997cited by this paper
• Global burden of disease.

  1997cited by this paper
• A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.

  1996cited by this paper
• Cost - Effectiveness Analysis, Extended Dominance, and Ethics

  1994cited by this paper

• Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients with Long-term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study.

  2024cites this paper
• Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence

  2023cites this paper
• Usage and cost-effectiveness of anti-psychotics in psychiatry OPD among various clinical conditions: A prospective observational study in a tertiary care center

  2023cites this paper
• Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

  2021cites this paper
• NDT_A_282856 125..137

  2021cites this paper
• A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway

  2020cites this paper
• Economic evaluation in the context of schizophrenia and related psychotic conditions: A systematic review and cost-consequence analysis

  2020cites this paper
• Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia

  2020cites this paper
• Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review

  2020cites this paper
• Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia

  2019cites this paper
• Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis

  2018cites this paper
• Systematic review of pharmacoeconomic models for schizophrenia

  2018cites this paper
• Cost-effectiveness of therapeutic interventions in schizophrenia

  2017cites this paper
• Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands

  2017influential citation
• PREFORMULATION STUDY OF ARIPIPRAZOLE FOR FORMULATION AND DEVELOPMENT OF NEWER ANTIPSYCHOTIC FORMULATION

  2017cites this paper
• DRUG CHARACTERIZATION STUDY OF ARIPIPRAZOLE FOR FORMULATION AND DEVELOPMENT OF NEWER ANTIPSYCHOTIC FORMULATION

  2017cites this paper
• Health-related quality of life in elderly: a review of the EQ-5D use

  2016influential citation
• Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs

  2016cites this paper
• An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance

  2016cites this paper
• Economic Evaluation Of Antipsychotics For The Treatment Of Schizophrenia: A Systematic Review

  2016influential citation
• Cost-effectiveness of atypical antipsychotics for the treatment of schizophrenia

  2016influential citation
• Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland

  2016cites this paper
• Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

  2015cites this paper
• Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia

  2014influential citation
• The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia

  2013cites this paper
• Validation of an economic model of paliperidone palmitate for chronic schizophrenia

  2013cites this paper
• Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study

  2013cites this paper
• The economic impact of mental health services and the need for cost reduction programs: suggestions from middle‐income countries

  2012cites this paper
• Sexual Dysfunction and Hyperprolactinemia in Male Psychotic Inpatients: A Cross-Sectional Study

  2011cites this paper
• Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge.

  2011cites this paper
• Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

  2011cites this paper
• Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia

  2011cites this paper
• Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States

  2010cites this paper
• The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.

  2010cites this paper
• Estudio de costo-efectividad del tratamiento de la esquizofrenia en México*

  2010cites this paper
• Evidence-Based Practice Problems: Form and Focus

  2010cites this paper
• Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

  2009cites this paper
• Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social. Assessment of typical and atypical antipsychotics

  2009cites this paper
• Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics.

  2009cites this paper
• Service Utilization and Costs Associated With Switching to Risperidone from Previous Treatment with Typical Antipsychotic Agents

  2009cites this paper
• Current awareness in human psychopharmacology

  2008cites this paper
• Current awareness in human psychopharmacology.

  2008cites this paper
• Comments on ‘Cost‐effectiveness of antipsychotics for outpatients with chronic schizophrenia’

  2008cites this paper
• Not for Sale or Commercial Distribution

  2007cites this paper
• Vii. Referencias

  year unknowncites this paper